Subscribe
shutterstock_1396958150_pavel_kapysh-2
Pavel Kapysh / Shutterstock.com
28 January 2021AmericasMuireann Bolger

FTC hits Amneal, Impax and Endo with antitrust suit

The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Allergan settles patent dispute with Amneal
1 September 2016   Dublin-based pharmaceutical company Allerganhas revealed that its subsidiaries, Forest Laboratories and Adamas Pharmaceuticals, have entered into a settlement agreement with Amneal Pharmaceuticals.
Americas
FTC approves Amneal’s $1.45bn acquisition of Impax
11 July 2018   The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.
Big Pharma
Irish pharma company prevails in US pay-for-delay case
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Allergan settles patent dispute with Amneal
1 September 2016   Dublin-based pharmaceutical company Allerganhas revealed that its subsidiaries, Forest Laboratories and Adamas Pharmaceuticals, have entered into a settlement agreement with Amneal Pharmaceuticals.
Americas
FTC approves Amneal’s $1.45bn acquisition of Impax
11 July 2018   The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.
Big Pharma
Irish pharma company prevails in US pay-for-delay case
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.

More on this story

Americas
Allergan settles patent dispute with Amneal
1 September 2016   Dublin-based pharmaceutical company Allerganhas revealed that its subsidiaries, Forest Laboratories and Adamas Pharmaceuticals, have entered into a settlement agreement with Amneal Pharmaceuticals.
Americas
FTC approves Amneal’s $1.45bn acquisition of Impax
11 July 2018   The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.
Big Pharma
Irish pharma company prevails in US pay-for-delay case
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent